Holen Sie sich die Stockscreener-App
337.60
1.19%
-4.06
Handel nachbörslich:
336.60
-1.00
-0.30%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Why Amgen’s Repatha is quietly reshaping cholesterol therapy - AD HOC NEWS
Amgen Growth Drivers Surge 24 Percent as New Core Takes Over - HarianBasis.co
Amgen vs. NovoCure: Which Health Care Stock Is a Better Buy in 2026? - Yahoo Finance
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know - Yahoo! Finance Canada
Amgen StockGoldman Sachs trims target after obesity pipeline update - AD HOC NEWS
Amgen Rhode Island - Providence Business News
Amgen Gives Greater Los Angeles Community an Experience to Remember at FIFA Fan Festival - Amgen
What If Amgen Stock's Patent Worries Are Hiding Its Real Growth Engine? - Yahoo Finance
What If Amgen Stock’s Patent Worries Are Hiding Its Real Growth Engine? - Trefis
Medtronic Ruling Supports IRS In Amgen Case, Tax Court Told - Law360
Amgen Inc. stock outperforms competitors despite losses on the day - MarketWatch
Amgen's Diversified Business, Emerging Pipeline Drives Positive View, RBC Says - Moomoo
RBC Capital Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $370 - Moomoo
Amgen (AMGN) Sees a More Significant Dip Than Broader Market: Some Facts to Know - sharewise.com
Amgen Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Amgen Stock’s Gross Margin Story in Q1 2026: What the Numbers Say About a $468 Target - TIKR.com
Amgen Ends Lobbying Relationship With DC Firm - Legis1
How Patent Setback and Drug Wins Will Impact Amgen (AMGN) Investors - simplywall.st
Competitive tension builds around Amgen's Tepezza after a fresh patent ruling - AD HOC NEWS
Amgen Hires Lobbying Counsel on Drug Pricing - Legis1
New phase 3 data put Amgen’s Repatha back in the lipid spotlight - AD HOC NEWS
Amgen Inc. Stock (US0311621009): Jury patent verdict and valuation debate put shares in focus - AD HOC NEWS
Amgen Owes $20 Million in Antibody-Production Tech Patent Trial - Bloomberg Law News
Harbour BioMed Wins $20 Million Patent Verdict Against Amgen - Contract Pharma
AMGN DCF Analysis: Intrinsic Value $292 vs Price $355 - GuruFocus
The litigation lasted five years, and Amgen was found to have willfully infringed. Harbour BioMed stated, 'The favorable ruling is expected to enhance our BD negotiation leverage.' | Quick Read Announcement - 富途牛牛
Amgen Inc. (AMGN) Stock Report: Valuation Insights Amid Robust Dividend Yield and Revenue Growth - DirectorsTalk Interviews
Internal documents reveal: Denmark sues Amgen for millions following MFN exit - medwatch.com
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape - PR Newswire
Amgen Inc. (AMGN) is attracting investor attention: Here is what you should know - MSN
Amgen’s Repatha Data Highlights at ADA 2026 Amid Analyst Price Target AdjustmentEarnings Call Highlights - newsline.com
Amgen Repatha Data Highlights Potential in Longevity Sector Following ADA PresentationRevenue Miss Report - newsline.com
Amgen's Repatha Data Bolsters Longevity Profile Amid Analyst Price Target AdjustmentLow Estimate Range - newsline.com
Amgen Shows Repatha Risk Reduction in High-Risk Diabetes Patients; Goldman Sachs Adjusts Price TargetProfit Warning Alert - newsline.com
Healthcare of Ontario Pension Plan Trust Fund Sells 64,867 Shares of Amgen Inc. $AMGN - MarketBeat
Amgen Cuts Cardiovascular Risk in High Risk Diabetes Patients - HarianBasis.co
Atlas Capital Advisors Inc. Takes $2.20 Million Position in Amgen Inc. $AMGN - MarketBeat
Amgen (AMGN) Stock Valuation Looks Split Between Analyst Targets And DCF Upside - simplywall.st
Morgan Stanley Raises Amgen (AMGN) Price Target Following a Strong Start for Uplizna - Insider Monkey
Wall Street Zen Upgrades Amgen (NASDAQ:AMGN) to Buy - MarketBeat
Amgen Inc. Stock (US0311621009): Biotech heavyweight in focus as investors weigh valuation and pipel - AD HOC NEWS
Victory Capital Management Inc. Grows Holdings in Amgen Inc. $AMGN - MarketBeat
State Street Corp Has $10.01 Billion Stock Position in Amgen Inc. $AMGN - MarketBeat
Van ECK Associates Corp Lowers Position in Amgen Inc. $AMGN - MarketBeat
Is Amgen Still Reasonable After Its Strong Run? - Kalkine Media
Here’s Why Amgen (AMGN) is Among the 7 Best Longevity Stocks to Buy Now - Insider Monkey
Korea Investment CORP Trims Stake in Amgen Inc. $AMGN - MarketBeat
Operating expenses (excl. COGS) of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Rhenman & Partners Asset Management AB Acquires Shares of 36,000 Amgen Inc. $AMGN - MarketBeat
First National Bank of Omaha Boosts Position in Amgen Inc. $AMGN - MarketBeat
Amgen taps research firm to reassess Tavneos data - Reuters
Amgen (AMGN) Stock After Horizon Deal And Strong Multi‑Year Gains Is Price Still Reasonable - simplywall.st
Jury Tells Amgen To Pay $20.2M In Antibody Patent Trial - Law360
Amgen owes $20.2 million in antibody patent lawsuit, US jury says - marketscreener.com
Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs Trade Ideas — BCBA:AMGN.CI - TradingView
Amgen Defends Rare Disease Drug in FDA Crosshairs - MedCity News
Amgen owes $20.2 mln in antibody patent lawsuit, US jury says - TradingView
Amgen Defends Tavneos Amid FDA Withdrawal Proposal - GuruFocus
Amgen Seeks FDA Hearing To Challenge Proposed Tavneos Withdrawal - Benzinga
Amgen’s ABP 938 Takes Aim at EYLEA HD in High-Stakes Eye Disease Trial - TipRanks
Cash from investing activities of Amgen Inc. Shs Cert Deposito Arg Repr 0.033333 Shs – BCBA:AMGN.CI - TradingView
Piper Sandler reiterates Amgen stock rating on Sjogren’s drug - Investing.com
Piper Sandler reiterates Amgen stock rating on Sjogren’s drug By Investing.com - Investing.com Canada
Amgen's $500 Million Tavneos Faces FDA Withdrawal Fight - GuruFocus
0.76%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):